CSL strikes $1.6 billion rare disease drug deal with Alentis
Australia's CSL will pay up to $1.6 billion to co-develop Alentis Therapeutics' lixudebart for rare kidney and liver diseases.
Simple explainers on world affairs, science, health and more.
All news under one minute
Australia's CSL will pay up to $1.6 billion to co-develop Alentis Therapeutics' lixudebart for rare kidney and liver diseases.
Notre Dame researchers found that combining belzutifan with TRAIL protein kills aggressive kidney cancer cells in lab studies.
Candel Therapeutics will present lung cancer and glioblastoma immunotherapy data at the Society for Immunotherapy of Cancer's annual meeting in November.
Psychologist Dr Carrie Mackensen warns that AI chatbots designed to agree with kids can harm their developing brains.
Dozens hospitalised in Ballia, UP after eating millet flour rotis before the Jyutiya fast; food samples sent for testing.
VB Spine's ScolimiR-3D, a microRNA blood test that predicts scoliosis progression in teens, received FDA Breakthrough Device Designation.
Human tau proteins from Alzheimer's and CBD patients forced mouse tau to copy their exact disease-specific shapes, a Nature study shows, strengthening…
Cedars-Sinai scientists have found that restoring the UBE2N enzyme reduced liver fat, inflammation and scarring in mice.
A 104-week trial of 493 adults found diet beverages equivalent to water for long-term weight management.
Survey reported by Newsweek finds women using midwives more likely to report postpartum mental health issues, though aftercare may be better.